This segment focuses on developing and commercializing therapies for chronic pain, utilizing BioDelivery Sciences' innovative drug delivery technologies. Key products include BELBUCA, a buprenorphine buccal film for chronic pain, and ELYXYB, a celecoxib oral solution for migraine treatment. Research and development efforts are directed towards improving drug efficacy, reducing side effects, and enhancing patient compliance through advanced formulations and delivery methods. The BEMA (BioErodible MucoAdhesive) technology plays a crucial role in this segment, offering a non-invasive and convenient route of administration. The segment addresses the significant unmet needs of patients suffering from chronic pain conditions, aiming to improve their quality of life and reduce reliance on traditional opioid medications. Future opportunities include expanding the product pipeline with novel pain management therapies and exploring new applications of the BEMA technology.

This segment is dedicated to addressing the side effects associated with opioid use, specifically opioid-induced constipation. The primary product in this segment is Symproic, a peripherally acting mu-opioid receptor antagonist (PAMORA) designed to alleviate OIC in adult patients with chronic non-cancer pain. Research and development activities focus on optimizing the formulation and delivery of PAMORAs to maximize their effectiveness and minimize systemic exposure. The segment aims to improve the overall well-being of patients on long-term opioid therapy by mitigating the debilitating effects of OIC. Market positioning involves highlighting the unique benefits of Symproic compared to other OIC treatments, emphasizing its targeted action and reduced potential for drug interactions. Future growth potential lies in expanding the indications for Symproic and developing new PAMORA-based therapies for other opioid-related side effects.